11 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00779 | A12L | KWKSFLKTFKSLKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 5.2 µMo/L |
| dbacp00787 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.4 µMo/L |
| dbacp00795 | A12L/A20L/A23L | KWKSFLKTFKSLKKTVLHTLLKLISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.6 µMo/L |
| dbacp00803 | A20L | KWKSFLKTFKSAKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 7.8 µMo/L |
| dbacp03576 | L17A | KWKSFLKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : > 83.6 µMo/L |
| dbacp03584 | L17A/L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp03595 | L21A | KWKSFLKTFKSAKKTVAHTAAKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 63.5 µMo/L |
| dbacp03619 | L6A | KWKSFAKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 62.5 µMo/L |
| dbacp03627 | L6A/L17A | KWKSFAKTFKSAKKTVAHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : >83.6 µMo/L |
| dbacp05027 | Peptide P | KWKSFLKTFKSAKKTVLHTALKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 11.5 µMo/L |
| dbacp08045 | R11-NLS-pep8 | RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa | NKp44 derived synthetic peptide | NKp44-pep8 inhibits PCNA function | PrestoBlue assay | B-16 | Skin Cancer | ED50 = 7.1 μM |